Rivaroxaban Pharmacology
Published April 18, 2019
|
16 min
    Download
    Add to queue
    Copy URL
    Show notes
    Rivaroxaban is a factor 10a inhibitor that inhibits clot formation and thins the blood.



    Rivaroxaban needs to be monitored for bleed risk. Checking periodic CBC can help us assess if hemoglobin and hematocrit are remaining stable.



    Enzyme inducers like rifampin, St. John's Wort, and carbamazepine can reduce concentrations and increase the risk of treatment failure.



    NSAIDs and antiplatelet medications can significantly increase the risk of bleed with rivaroxaban.



    Rivaroxaban should not be used with dual P-glycoprotein and CYP3A4 inhibitors. Examples include ketoconazole, itraconazole, and ritonavir.
      15
      15
        0:00:00 / 0:00:00